RAD51 polymorphisms were associated with symptoms of heart failure according to NYHA class and the occurrence of a new primary tumor, while XRCC3 polymorphisms were associated with tumor differentiation and skin adverse events according to LENT-SOMA criteria. This evidence concerns the gene XRCC3 and neoplasm.